Consensus statement on indications for the use of non-pegylated liposomal doxorubicin in patients with lymphomas and concomitant cardiovascular diseases Consensus
Article Sidebar
Published:
Oct 1, 2013
Main Article Content
Abstract
None
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Szmit S, Jędrzejczak WW, Opolski G. Consensus statement on indications for the use of non-pegylated liposomal doxorubicin in patients with lymphomas and concomitant cardiovascular diseases. OncoReview [Internet]. 2013Oct.1 [cited 2024Apr.29];3(3(11):213-5. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/345
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Curigliano G., Cardinale D., Suter T., Plataniotis G., de Azambuja E., Sandri M.T., Criscitiello C., Goldhirsch A., Cipolla C., Roila F.; ESMO Guidelines Working Group: Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann. Oncol. 2012; 23(supl. 7): vii155-66.
2. Jurczak W., Szmit S., Sobociński M., Machaczka M., Drozd-Sokołowska J., Joks M., Dzietczenia J., Wróbel T., Kumiega B., Zaucha J.M., Knopińska-Posłuszny W., Spychałowicz W., Prochwicz A., Drohomirecka A., Skotnicki A.B.: Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen – A national multicenter study. International Journal of Cardiology 2013; pii: S0167-5273(13)01558-1. https://doi.org/10.1016/j.ijcard.2013.08.033.
3. Moser E.C., Noordijk E.M., van Leeuwen F.E., le Cessie S., Baars J.W., Thomas J., Carde P., Meerwaldt J.H., van Glabbeke M., Kluin-Nelemans H.C.: Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006; 107(7): 2912-9.
4. Myrehaug S., Pintilie M., Yun L., Crump M., Tsang R.W., Meyer R.M., Sussman J., Yu E., Hodgson D.C.: A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood 2010; 116: 2237-40.
5. Rigacci L., Mappa S., Nassi L., Alterini R., Carrai V., Bernardi F., Bosi A.: Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol. Oncol. 2007; 25: 198-203.
6. Fridrik M., Petzer A., Keil F. et al.: Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial. Blood 2011; 2676.
7. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., Shah P., Khojasteh A., Nair M.K., Hoelzer K., Tkaczuk K., Park Y.C., Lee L.W.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001; 19(5): 1444-54.
8. Batist G., Harris L., Azarnia N., Lee L.W., Daza-Ramirez P.: Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006; 17(5): 587-95.
2. Jurczak W., Szmit S., Sobociński M., Machaczka M., Drozd-Sokołowska J., Joks M., Dzietczenia J., Wróbel T., Kumiega B., Zaucha J.M., Knopińska-Posłuszny W., Spychałowicz W., Prochwicz A., Drohomirecka A., Skotnicki A.B.: Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen – A national multicenter study. International Journal of Cardiology 2013; pii: S0167-5273(13)01558-1. https://doi.org/10.1016/j.ijcard.2013.08.033.
3. Moser E.C., Noordijk E.M., van Leeuwen F.E., le Cessie S., Baars J.W., Thomas J., Carde P., Meerwaldt J.H., van Glabbeke M., Kluin-Nelemans H.C.: Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006; 107(7): 2912-9.
4. Myrehaug S., Pintilie M., Yun L., Crump M., Tsang R.W., Meyer R.M., Sussman J., Yu E., Hodgson D.C.: A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood 2010; 116: 2237-40.
5. Rigacci L., Mappa S., Nassi L., Alterini R., Carrai V., Bernardi F., Bosi A.: Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol. Oncol. 2007; 25: 198-203.
6. Fridrik M., Petzer A., Keil F. et al.: Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial. Blood 2011; 2676.
7. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., Shah P., Khojasteh A., Nair M.K., Hoelzer K., Tkaczuk K., Park Y.C., Lee L.W.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001; 19(5): 1444-54.
8. Batist G., Harris L., Azarnia N., Lee L.W., Daza-Ramirez P.: Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 2006; 17(5): 587-95.